vs
Side-by-side financial comparison of Nutex Health, Inc. (NUTX) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $151.7M, roughly 1.1× Nutex Health, Inc.). Nutex Health, Inc. runs the higher net margin — 7.8% vs -82.0%, a 89.8% gap on every dollar of revenue. On growth, PTC THERAPEUTICS, INC. posted the faster year-over-year revenue change (-22.7% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $-36.6M). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs -11.5%).
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
NUTX vs PTCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $151.7M | $164.7M |
| Net Profit | $11.8M | $-135.0M |
| Gross Margin | 30.4% | — |
| Operating Margin | 20.4% | -43.3% |
| Net Margin | 7.8% | -82.0% |
| Revenue YoY | -41.1% | -22.7% |
| Net Profit YoY | -80.8% | -104.8% |
| EPS (diluted) | $2.34 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $151.7M | $164.7M | ||
| Q3 25 | $267.8M | $211.0M | ||
| Q2 25 | $244.0M | $178.9M | ||
| Q1 25 | $211.8M | $1.2B | ||
| Q4 24 | $257.6M | $213.2M | ||
| Q3 24 | $78.8M | $196.8M | ||
| Q2 24 | $76.1M | $186.7M | ||
| Q1 24 | $67.5M | $210.1M |
| Q4 25 | $11.8M | $-135.0M | ||
| Q3 25 | $55.4M | $15.9M | ||
| Q2 25 | $-17.7M | $-64.8M | ||
| Q1 25 | $21.2M | $866.6M | ||
| Q4 24 | $61.6M | $-65.9M | ||
| Q3 24 | $-8.8M | $-106.7M | ||
| Q2 24 | $-364.0K | $-99.2M | ||
| Q1 24 | $-364.0K | $-91.6M |
| Q4 25 | 30.4% | — | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 51.2% | — | ||
| Q1 25 | 55.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 27.8% | — | ||
| Q2 24 | 29.7% | — | ||
| Q1 24 | 15.1% | — |
| Q4 25 | 20.4% | -43.3% | ||
| Q3 25 | 48.7% | 1.4% | ||
| Q2 25 | 13.8% | -19.5% | ||
| Q1 25 | 38.1% | 82.5% | ||
| Q4 24 | 44.4% | -76.2% | ||
| Q3 24 | 12.3% | -27.7% | ||
| Q2 24 | 7.0% | -21.5% | ||
| Q1 24 | 2.1% | -21.6% |
| Q4 25 | 7.8% | -82.0% | ||
| Q3 25 | 20.7% | 7.5% | ||
| Q2 25 | -7.3% | -36.3% | ||
| Q1 25 | 10.0% | 73.7% | ||
| Q4 24 | 23.9% | -30.9% | ||
| Q3 24 | -11.2% | -54.2% | ||
| Q2 24 | -0.5% | -53.1% | ||
| Q1 24 | -0.5% | -43.6% |
| Q4 25 | $2.34 | $-1.63 | ||
| Q3 25 | $7.76 | $0.20 | ||
| Q2 25 | $-2.95 | $-0.83 | ||
| Q1 25 | $3.33 | $10.04 | ||
| Q4 24 | $11.56 | $-0.85 | ||
| Q3 24 | $-1.72 | $-1.39 | ||
| Q2 24 | $-0.07 | $-1.29 | ||
| Q1 24 | $-0.08 | $-1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $185.6M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $329.4M | $-205.3M |
| Total Assets | $918.5M | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $185.6M | $1.9B | ||
| Q3 25 | $166.0M | $1.7B | ||
| Q2 25 | $96.7M | $2.0B | ||
| Q1 25 | $84.7M | $2.0B | ||
| Q4 24 | $40.6M | $1.1B | ||
| Q3 24 | $46.9M | $1.0B | ||
| Q2 24 | $40.8M | $1.1B | ||
| Q1 24 | $30.0M | $884.8M |
| Q4 25 | $329.4M | $-205.3M | ||
| Q3 25 | $317.2M | $-155.8M | ||
| Q2 25 | $235.3M | $-206.5M | ||
| Q1 25 | $176.9M | $-185.8M | ||
| Q4 24 | $132.4M | $-1.1B | ||
| Q3 24 | $60.4M | $-1.1B | ||
| Q2 24 | $62.7M | $-980.2M | ||
| Q1 24 | $63.0M | $-893.9M |
| Q4 25 | $918.5M | $2.9B | ||
| Q3 25 | $964.5M | $2.6B | ||
| Q2 25 | $841.0M | $2.6B | ||
| Q1 25 | $761.9M | $2.7B | ||
| Q4 24 | $655.3M | $1.7B | ||
| Q3 24 | $438.5M | $1.8B | ||
| Q2 24 | $422.4M | $1.9B | ||
| Q1 24 | $404.3M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $70.4M | $-34.3M |
| Free Cash FlowOCF − Capex | $69.0M | $-36.6M |
| FCF MarginFCF / Revenue | 45.5% | -22.3% |
| Capex IntensityCapex / Revenue | 0.9% | 1.4% |
| Cash ConversionOCF / Net Profit | 5.95× | — |
| TTM Free Cash FlowTrailing 4 quarters | $245.6M | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.4M | $-34.3M | ||
| Q3 25 | $99.5M | $-66.3M | ||
| Q2 25 | $27.3M | $-58.3M | ||
| Q1 25 | $51.0M | $870.1M | ||
| Q4 24 | $54.0K | $-30.0M | ||
| Q3 24 | $6.8M | $-77.0M | ||
| Q2 24 | $13.3M | $-71.5M | ||
| Q1 24 | $3.1M | $70.8M |
| Q4 25 | $69.0M | $-36.6M | ||
| Q3 25 | $99.2M | $-69.7M | ||
| Q2 25 | $26.5M | $-59.6M | ||
| Q1 25 | $50.9M | $868.4M | ||
| Q4 24 | $-341.0K | $-33.8M | ||
| Q3 24 | $6.2M | $-77.5M | ||
| Q2 24 | $12.7M | $-78.8M | ||
| Q1 24 | $2.3M | $61.2M |
| Q4 25 | 45.5% | -22.3% | ||
| Q3 25 | 37.0% | -33.1% | ||
| Q2 25 | 10.9% | -33.3% | ||
| Q1 25 | 24.0% | 73.8% | ||
| Q4 24 | -0.1% | -15.8% | ||
| Q3 24 | 7.8% | -39.4% | ||
| Q2 24 | 16.7% | -42.2% | ||
| Q1 24 | 3.4% | 29.1% |
| Q4 25 | 0.9% | 1.4% | ||
| Q3 25 | 0.1% | 1.6% | ||
| Q2 25 | 0.3% | 0.7% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.2% | 1.8% | ||
| Q3 24 | 0.8% | 0.3% | ||
| Q2 24 | 0.7% | 4.0% | ||
| Q1 24 | 1.1% | 4.6% |
| Q4 25 | 5.95× | — | ||
| Q3 25 | 1.80× | -4.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.40× | 1.00× | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
PTCT
Segment breakdown not available.
